ALNYLAM PHARMACEUTICALS, INC. (ALNY) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ALNYLAM PHARMACEUTICALS, INC.'s filing signal turned positive.

Alnylam Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing RNA interference (RNAi) therapeutics. Leveraging its RNAi platform, the company has brought six first-in-class RNAi-based medicines to market, including AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Leqvio (commercialized by Novartis), and Qfitlia (commercialized by Sanofi). Alnylam targets genetically validated genes implicated in human diseases, utilizing delivery technologies like GalNAc conjugates for liver delivery and C16 moieties for CNS and ocular delivery. The company's strategy centers on addressing unmet medical needs in both rare and prevalent diseases, with a significant focus on its TTR franchise and expanding its pipeline across multiple tissue types.

Revenue is primarily driven by net product sales from its marketed RNAi therapeutics, including AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO. Additionally, the company generates revenue from collaborations and royalties on sales of products commercialized by its partners, such as Leqvio and Qfitlia.